Skip to main content
. Author manuscript; available in PMC: 2020 May 20.
Published in final edited form as: J Invest Dermatol. 2018 Jul 17;139(1):100–107. doi: 10.1016/j.jid.2018.04.041

Figure 1.

Figure 1.

Study Overview

Participants were assessed at baseline, week one and week 12 of therapy. Participant sampling comprised blood testing, urine collection, lesional and non-lesional skin biopsies (from photoprotected sites on the lower back/buttock, from the edge of plaques and at a minimum distance from previous biopsy sites). RNA-Seq was conducted on mRNA from blood, lesional and non-lesional skin and miRNA from blood. Proteomic assessment was conducted on serum.